New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
13:05 EDTABTAbbott says over 2,000 patients to be included in phase 3 program for HCV
Abbott released details on its phase 3 hepatitis C registrational program following results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease in Boston. Topline intent-to-treat results from the 12-week, triple-DAA regimens with ribavirin presented at the AASLD meeting this week found that 97.5%, or 77 of 79, of treatment-na´ve GT1 patients and 93.3%, or 42 of 45, in GT1 null responder patients achieved SVR12. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals, with and without ribavirin, for the treatment of HCV in genotype 1 non-cirrhotic, treatment-na´ve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks. The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r, ABT-267 and ABT-333. Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials, the company said.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
April 14, 2014
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
April 10, 2014
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
April 9, 2014
11:43 EDTABTGilead defended by analysts after recent pullback
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use